Cognitive Impairment in Older Adults With Hematologic Malignancies

NCT07842679 | Not Yet Recruiting

• 1 other identifier: Cognitive-Hematology-Assiut-20
• Study Type: observational
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.

Conditions

Cognitive Impairment; Hematologic Malignancies; Chemotherapy Effect

Keywords

Cognitive impairment; Hematologic malignancies; Assiut; MoCA; Activities of daily living; Older adults

Outcome Measures

Primary Outcomes (1)

• Prevalence of cognitive impairment

  Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26.

  Baseline

Secondary Outcomes (5)

• Mean MoCA score

  Baseline

• Mean Katz ADL score

  Baseline

• Mean Lawton IADL score

  Baseline

• Proportion with impaired activities of daily living

  Baseline

• Proportion with impaired instrumental activities of daily living

  Baseline

Study Arms (1)

Single cohort: Older adults with hematologic malignancies

Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment.

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.

You may qualify if:

• \- Age 65 years or older
• Confirmed diagnosis of hematologic malignancy
• Currently receiving chemotherapy
• Able to communicate and participate in cognitive assessment
• Written informed consent

You may not qualify if:

• \- Previously diagnosed dementia before the diagnosis of malignancy
• Delirium at the time of assessment
• Severe visual or hearing impairment interfering with cognitive testing
• History of major neurological disorders affecting cognition
• Severe psychiatric illness affecting cognitive assessment
• Critically ill patients unable to complete study assessment

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Cognitive Dysfunction; Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Soher M kasem, prof

  Internal Medicine Department, Assiut University Hospitals

  STUDY CHAIR

Central Study Contacts

Kholoud K Fawzy, Resident

CONTACT

01009850621; khloud.18313604@med.aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident Physician, Department of Internal Medicine - Geriatrics

Study Record Dates

• First Submitted: September 21, 2026
• First Posted: September 25, 2026
• Study Start: September 26, 2026
• Primary Completion (Estimated): September 26, 2027
• Study Completion (Estimated): February 25, 2028
• Last Updated: September 28, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share